You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A novel RF coil and incubator for reducing acoustic noise in neonatal MRI

    SBC: NeoView, Inc.            Topic: NICHD

    PROJECT SUMMARY In this Phase I Small Business Technology TransferSTTRprojecta team of researchers at Cincinnati Childrenandapos s Hospital Medical CenterCCHMCwill work with the engineering team at NeoViewIncto design and build novel body coil and incubator prototypes for aTesla Neonatal Intensive Care UnitNICUMRI systemThese components will play a central role in NeoViewandapos s neonatal MRI pro ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Catheter Based Cardiovascular Device Retrieval System

    SBC: Onocor LLC            Topic: NHLBI

    During the past decade there has been an exponential growth in the numberscope and complexity of catheter based interventions for structural heart diseaseTranscatheter aortic valve replacementTAVRendovascular aneurysm repairEVARvena caval filters and intracardiac defect closure are all well developed and growing treatment strategiesThe recent FDA approval of left atrial appendageLAAocclusion for a ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Making Standing Balance The Fifth Vital Sign in Clinical Settings

    SBC: BERTEC CORP            Topic: NIA

    Falls are a significant source of early morbidity and mortality in the aging populationyet the neurologicalsensoryand motor changes that lead to increased fall risk often escape early identification and interventionVital signs are commonly used in clinical settings to assess the cardiovascular systemblood pressureheart rateimmune systembody temperatureand the respiratory systemrespiratory rateto e ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Astrocyte activation by small-molecule ADORA3 agonists: a novel therapy for Alzheimer's disease

    SBC: ASTROCYTE PHARMACEUTICALS INC.            Topic: NIA

    PROJECT SUMMARY Alzheimerandapos s diseaseADis an area of significant unmet need that creates a national burden of$billion annuallyAD is the leading cause of dementiaaffectingof Americans over the age ofDemographic shifts and the age related nature of AD will soon place this disease as the costliest health care expenditure in the U Swith a projected impact of $trillion per year byCurrent therapies ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. A practical platform for in-home remote monitoring of cognitive-frailty

    SBC: BIOSENSICS LLC            Topic: NIA

    AbstractCognitive frailtythe combined presence of physical frailty and cognitive impairmentis a strong and independent predictor of cognitive declineThe International Association of Gerontology and Geriatrics and the International Academy on Nutrition and Aging have recommended the use of cognitive frailty assessment to track the progression of mild cognitive impairmentMCItowards dementiaAlzheimer ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.

    SBC: ARCHER PHARMACEUTICALS, INC.            Topic: NIA

    Pathological hallmarks of Alzheimerandapos s diseaseADinclude extracellular deposits of Apeptidesintraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammationMost proposed AD disease modifying therapies have focused on strategies that reduce brain Aamyloid or tau pathological accumulationHoweversuch approaches have been unsuccessful in late stage AD clinical trials and ma ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD

    SBC: MASSACHUSETTS GENERAL HOSPITAL            Topic: NIA

    Abstract Overmillion Americans are currently affected by Alzheimerandapos s diseaseADwith an economic burden estimated at andgt$billion year inthat is projected increase at least four fold over next several decadesIn spite of the dearth of pharmacological options to modify the course of the disease at presentthe field has developed accurate biomarkers that demonstrate that the pathology of AD is p ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1

    SBC: VELUM INC            Topic: NIA

    There is a world wide twin epidemic of obesity and TypeDiabetesT Dwith an urgent need to find effective new drug treatments for inducing weight lossStable derivatives of the endogenous glucoregulatory hormoneglucagon like peptideGLPare in clinical use for the treatment of T D but are of equally great interest as an emerging treatment of obesity and of age related neurodegenerative conditions inclu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Production and quality analysis of clinical drug for a novel CNS protein kinase inhibitor therapeutic candidate

    SBC: NeuroKine Therapeutics, LLC            Topic: NIA

    ABSTRACT Alzheimer s diseaseADand related dementias are increasing rapidly yetremarkablythere are no approved disease modifying drugsVirtually all trials targeting amyloid related pathways have failed over the lastyearsRegrettablyfew alternative targets or pathways have been exploredThereforethere is an urgent need to explore alternative pathways as monotherapies or as constituents of a multi drug ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Technology for the non-invasive surveilance of post-traumatic compartment syndrome

    SBC: MYOLEX, INC.            Topic: NIAMS

    PROJECT SUMMARYAcute compartment syndromeACSremains one of the most devastating and often overlooked traumatic musculoskeletal disorders in clinical practiceIn this conditionpressure increases in one of the body s spacelimited compartmentsdue most commonly to direct trauma or bone fractureresulting ultimately in an ischemic injury to all of the compartment s contentsincluding muscle and nerveOnce ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government